Novartis India Faces Open Offer Post Promoter Stake Sale

Acquirers offer ₹860.64 per share for up to 26% of Novartis India.
Reader Takeaway: Open offer provides exit at premium; ongoing tax litigation poses a risk.

What just happened

WaveRise Investments Limited, ChrysCapital Fund X, and Two Infinity Partners, collectively the Acquirers, have announced a public open offer to acquire up to 64,19,608 equity shares of Novartis India Limited. This represents 26% of the company's voting share capital. The offer price is set at ₹860.64 per equity share. This move is a consequence of an agreement to purchase a 70.68% stake in Novartis India from the current promoter, Novartis AG.

Why this matters

This open offer signifies a change in control for Novartis India. It provides an opportunity for existing public shareholders to exit their investment at a premium price of ₹860.64 per share. The total potential consideration for the open offer, if fully subscribed, amounts to ₹552.50 crore.

The backstory

Novartis AG, the current promoter, is selling its significant stake in Novartis India. This transaction will lead to the Acquirers becoming the new promoters, and Novartis AG will be reclassified to the public shareholder category upon completion.

What changes now

The tendering period for the open offer is scheduled from June 11, 2026, to June 24, 2026. Shareholders have this window to decide whether to tender their shares at the offered price. Successful completion will result in a new promoter group taking control of the company.

Risks to watch

Novartis India is involved in significant ongoing tax-related litigation, including matters concerning income tax and sales tax. Potential cash outflows related to tax demands for products like Voveran 50 GE and Tegrital CR 200, which are currently under legal contest, represent a key risk for the company's financial health.

Peer comparison

Information regarding peer companies and their current market valuations is not directly available from the filing. However, the offer price of ₹860.64 per share can be compared against the company's historical performance and future outlook.

Context metrics (time-bound)

Novartis India reported revenue from operations of ₹354.33 crore for FY2026. Profit for FY2026 stood at ₹93.18 crore. This compares to FY2025 revenue of ₹356.27 crore and profit of ₹100.90 crore, and FY2024 revenue of ₹335.07 crore and profit of ₹85.19 crore.

What to track next

Investors should closely monitor the tendering process during the open offer period. Additionally, the outcome of the ongoing tax litigation will be crucial in assessing the company's future financial stability and profitability.